ArticleNature communications2026
ACAD8 deficiency promotes pathological cardiac hypertrophy in response to pressure overload by regulating histone isobutyrylation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Branched-chain amino acids play critical roles in cardiac physiology and diseases. Genetic deficiency in the valine catabolic enzyme ACAD8 is clinically associated with isobutyryl-CoA deregulation and cardiomyopathy in humans, but its roles in cardiac disease remain undefined. Here, we show that the levels of ACAD8 are reduced in humans and male mice with cardiac hypertrophy. Cardiomyocyte-specific Acad8 knockout in male mice exacerbates cardiac hypertrophy and cardiac dysfunction underwent pressure overload. Mechanistically, Acad8 deficiency leads to the accumulation of its substrate isobutyryl-CoA, which enhances histone isobutyrylation, chromatin accessibility and TEAD2 enrichment at promoter regions of hypertrophy-related genes, which increases the sensitivity to hypertrophic stress in mouse hearts and cardiomyocytes. Conversely, ACAD8 overexpression in cardiomyocytes suppresses isobutyryl-CoA accumulation and histone isobutyrylation, thereby attenuating cardiac hypertrophy and dysfunction. These results elucidate the roles of ACAD8 deficiency in cardiac diseases and reveal histone isobutyrylation in transcription regulation and cardiac pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.